Zauderer, Marjorie G. http://orcid.org/0000-0001-5426-0885
Alley, Evan W.
Bendell, Johanna
Capelletto, Enrica
Bauer, Todd M.
Callies, Sophie
Szpurka, Anna M.
Kang, Suhyun
Willard, Melinda D.
Wacheck, Volker
Varghese, Anna M.
Article History
Received: 15 January 2021
Accepted: 11 February 2021
First Online: 4 March 2021
Declarations
:
: The study was funded by Eli Lilly and Company.
: This study was conducted in accordance with the Consensus ethics principles derived from international ethics guidelines, including the Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS), International Ethical Guidelines, International Council for Harmonisation Guidelines for Good Clinical Practice (ICH GCP), and applicable local regulations.
: All patients provided written informed consent before study entry.
: All authors have given final approval of this version of the manuscript.
: LY3023414 is an orally available PI3K/mTOR inhibitor, currently in development for the treatment of patients with advanced and/or metastatic cancer including malignant mesothelioma. This study evaluated safety and preliminary efficacy of LY3023414 monotherapy at the recommended phase 2 dose in patients diagnosed with advanced mesothelioma. Translational research was conducted to understand any association between genomic alteration and clinical activity observed by assessing tumor baseline samples. While limited by the number of tumor samples available, a lower than previously reported incidence of PI3K/mTOR pathway activating alterations (i.e., PTEN loss) was observed. No obvious association between change in tumor size and biomarkers assessed was identified in patients diagnosed with mesothelioma receiving LY3023414. Pharmacokinetic analysis showed similar properties reported in patients with other cancer type. LY3023414 has an acceptable safety profile with limited single-agent activity in an unselected group of patients with advanced mesothelioma.
: M. Zauderer reports grants to their institution for research from Eli Lilly and Company, Department of Defense, NCI, Atara Biotherapeutics for research, GSK, Epizyme, Polaris, Sellas Life Sciences, BMS, Millennium/Takeda, Atara, and Curis; advisory role from Takeda, Aldeyra Therapeutics, Atara Biotherapeutics, GSK, Novocure, Aldeyra, Epizyme; personal fees from Research to Practice, Medical Learning Institute and OncLive, and non-financial support from Roche outside the submitted work.E.W. Alley reports no conflict of interest or financial support.J. Bendell reports research grants from Gilead, Genentech/Roche, BMS, Five Prime, Eli Lilly and Company, Merck, MedImmune, Celgene, EMD Serono, Taiho, Macrogenics, GSK, Novartis, OncoMed, LEAP, TG Therapeutics, AstraZeneca, BI, Daiichi Sankyo, Bayer, Incyte, Apexigen, Koltan, SynDevRex, Forty Seven, Abbvie, Array, Onyx, Sanofi, Takeda, Eisai, Celldex, Agios, Cytomx, Nektar, ARMO, Boston Biomedical, Ipsen, Merrimack, Tarveda, Tyrogenex, Oncogenex, Marshall Edwards, Pieris, Mersana, Calithera, Blueprint, Evelo, FORMA, Merus, Jacobio, Effector, Novocare, Arrys, Tracon, Sierra, Innate, Arch Oncology, Prelude Therapeutics, Unum Therapeutics, Vyriad, Harpoon, ADC, Amgen, Pfizer, Millennium, Imclome, Acerta Pharma, Rgenix, Bellicum, Gossamer Bio, Arcus Bio, Seattle Genetics, Tepest Tx, Shattuck Labs, Synthorx, Inc., Revolution Medicines, Inc., Bicycle Therapeutics, Zymeworks, Relay Therapeutics, Atlas Medx, Scholar Rock and NGM Biopharma, other payment to institution for consulting services from BMS, Five Prime, Eli Lilly and Company, Merck, Medimmune, Celgene, Taiho, Macrogenics, GSK, Novartis, OncoMed, LEAP, TG Therapeutics, AstraZeneca, BI, Daiichi Sankyo, Bayer, Incyte, Apexigen, Array, Sanofi, Agios, ARMO, Ipsen, Merrimack, Oncogenex, Evelo, FORMA, Innate, Arch Oncology, Prelude Therapeutics, Amgen, Pfizer, Seattle Genetics, Bicycle Therapeutics, Relay Therapeutis, Phoenix Bio, Cyteir, Molecular Partners, Torque, Tizona, Janssen, Tolero, TD2, Moderna Therapeutics, Tanabe Research Laboratories, Beigene, Continuum Clinical, Evelo, Piper Biotech, Samsung Bioepios, outside the submitted work.E. Capelleto reports other payment for consulting services from Boehringer Ingelheim and Astrazeneca; other payments for an advisory role at MSD, outside the submitted work.T. Bauer reports grants from Eli Lilly and Company, during the conduct of the study; grants from Daiichi Sankyo, grants from Medpacto, grants from Incyte, grants from Mirati Therapeutics, grants from MedImmune, grants from Abbvie, grants from AstraZeneca, grants from MabVax, grants from Stemline Therapeutics, grants from Merck, grants from Lilly, grants from GlaxoSmithKline, grants from Novartis, grants from Genentech, grants from Deciphera, grants from Merrimack, grants from Immunogen, grants from Millennium, grants from Phosplatin Therapeutics, grants from Calithera Biosciences, grants from Kolltan Pharmaceuticals, grants from Principa Biopharma, grants from Peleton, grants from Immunocore, grants from Roche, grants from Aileron Therapeutics, grants from Bristol-Myers Squibb, grants from Amgen, grants from Onyx, grants from Sanofi, grants from Boehringer-Ingelheim, grants from Astellas Pharma, grants from Five Prime Therapeutics, grants from Jacobio, grants from Top Alliance BioScience, grants from Janssen, grants from Clovis Oncology, grants from Takeda, grants from Karyopharm Therapeutics, grants from Foundation Medicine, grants from ARMO Biosciences, grants and other from Leap Therapeutics, grants, non-financial support and other from Ignyta, grants, non-financial support and other from Moderna Therapeutics, grants, personal fees and other from Pfizer, grants, personal fees and non-financial support from Loxo, grants, personal fees and non-financial support from Bayer, personal fees and non-financial support from Guardant Health, personal fees from Exelesis, outside the submitted work.S. Callies, A.M. Szpurka, S. Kang, M.D. Willard are employees of Eli Lilly and Company; M.D. Willard report other payments as a stockholder for Eli Lilly and Company.V. Wacheck reports payment as a former employee and shareholder for Eli Lilly and Company during the conduct of this study.